Bill > SF2392

This bill modifies Minnesota's prior authorization rules for prescription drugs, specifically focusing on mental health medications. The bill expands the existing prohibition on prior authorization for certain mental health-related drugs by removing previous restrictions and broadening the types of medications that cannot be subject to prior authorization or utilization management controls. Specifically, the bill now prevents prior authorization for central nervous system prescription drugs classified as anticonvulsants, antidepressants, antipsychotics, and noncontrolled substance antianxiety drugs used to treat mental illness. The bill also defines "utilization management controls" as formal techniques used by health carriers or prescription drug entities to monitor and evaluate drug use, including prior authorization processes and step therapy protocols. Additionally, the bill maintains existing provisions that protect certain drug approvals, such as automatic prior authorization for brand name drugs during a 60-day transition period when generic equivalents become available, and continues to exempt HIV and AIDS medications from prior authorization requirements. The changes aim to reduce barriers to accessing mental health medications and streamline the prescription drug approval process for patients and healthcare providers.

Health and Social Services

https://www.revisor.mn.gov/bills/bill.php?b=Senate&f=SF2392&ssn=0&y=2025